SHR-1701 + BP102

**SHR-1701 + BP102** is a combination therapy under investigation primarily for metastatic solid tumors such as metastatic colorectal cancer (mCRC) and recurrent or metastatic cervical cancer. **SHR-1701** is a bifunctional recombinant fusion protein combining a monoclonal antibody against programmed death ligand 1 (**PD-L1**) with the extracellular domain of transforming growth factor-beta receptor II (**TGF-βRII**). It acts as both an immune checkpoint inhibitor (by blocking PD-L1) and a TGF-β pathway inhibitor, targeting two key immunosuppressive mechanisms in the tumor microenvironment. **BP102** is a biosimilar of bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), used to inhibit tumor angiogenesis. This combination, often deployed alongside XELOX chemotherapy (capecitabine and oxaliplatin), is being tested for its additive or synergistic antitumor effects in first-line treatment of metastatic disease, particularly mCRC and cervical cancer. The combination aims to enhance immune activity, block immunosuppression, and reduce angiogenesis, leading to improved response rates and disease control[1][3][5].